

HEDGEYE



HEALTH CARE EVENT

Executive Insights: CRC Screening Outlook w/ Geneoscopy | The RNA Opportunity

An interview with Geneoscopy Co-Founders
Erica Barnell (Chief Scientific Officer) and
Andrew Barnell (Chief Executive Officer)

September 13, 2:30 PM ET

GENEOSCOPY

*The colorectal cancer **prevention** company*



Hedgeye Health Care

Tom Tobin, Managing
Director, Health Care

Ttobin@Hedgeye.com

@HedgeyeHC

William McMahon, Analyst,
Health Care

Wmcmahon@Hedgeye.com

@HedgeyeMed

Justin Venneri, Director,
Primary Research

Jvenneri@hedgeye.com

@HedgeyeJVenneri

DISCLAIMER

The preceding has been presented for informational purposes only. None of the information contained herein constitutes an offer to sell, or a solicitation of an offer to buy any security or investment vehicle, nor does it constitute an investment recommendation or legal, tax, accounting or investment advice by Hedgeye or any of its employees, officers, agents or guests. This information is presented without regard for individual investment preferences or risk parameters and is general, non-tailored, non-specific information. This content is based on information from sources believed to be reliable. Hedgeye is not responsible for errors, inaccuracies or omissions of information. The opinions and conclusions contained in this report are those of the individual expressing those opinions or conclusion and are intended solely for the use of Hedgeye's subscribers and the authorized recipients of the content. All investments entail a certain degree of risk and financial instrument prices can fluctuate based on several factors, including those not considered in the preparation of the content. Consult your financial professional before investing.

TERMS OF USE

The information contained herein is protected by United States and foreign copyright laws and is intended solely for the use of its authorized recipient. Access must be provided directly by Hedgeye. Redistribution or republication is strictly prohibited. For more detail please refer to the Terms of Service at https://www.hedgeye.com/terms_of_service.

About the Speakers


Erica Barnell, Ph.D., is Co-Founder & Chief Science Officer of Geneoscopy. Dr. Barnell graduated from Cornell University with a dual degree in Biological Sciences and Applied Economics & Management and is an MD/Ph.D. candidate at the Washington University School of Medicine. In 2019, she completed her Ph.D. at the McDonnell Genome Institute. Her thesis work surrounded the development of bioinformatic tools to alleviate the analysis bottleneck within precision oncology. Dr. Barnell has published 19 peer-reviewed manuscripts, 11 abstracts with 4 platform presentations, and two book chapters within the oncology space. She conducted the original research to validate Geneoscopy's stool extraction method and managed all feasibility studies for Geneoscopy's colorectal cancer (CRC) screening test and was responsible for existing engagement with the FDA, which includes holding three presubmission meetings and obtaining Breakthrough Device Designation for the lead CRC screening test. Dr. Barnell is the lead inventor on all patents pertaining to Geneoscopy's technology and is currently the site investigator on two IRB-approved protocols.

Andrew Barnell, MBA, is Co-Founder & CEO of Geneoscopy. Andrew graduated from Cornell University with a Bachelor's degree in Applied Economics & Management and a specialization in Finance. He received an MBA in Health Care Management and Entrepreneurial Management from The Wharton School. Andrew began his career as a financial analyst in J.P. Morgan's healthcare investment banking group, working primarily on M&A and capital markets transactions. He also worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on partnering with family-owned businesses.

Exact Sciences (EXAS)

HEDGEYE

Claims Index, Weekly



Sticking with the Short

We remain Short EXAS and believe there may be a potential inflection point given a combination of factors.


Recall that during the 2Q21 earnings season, management raised guidance, but cut screening revenue.

Additionally, there seems to be a discord here - any pressure on Cologuard volume due to competition and other companies' trials or colonoscopy volume should impact NTM and 2022 estimates.

We will dig into our colonoscopy claims data to see how volume and backlog are trending.

Exact Sciences, Claims Index vs. Screening Revenue

Cologuard Claims Look Weak in 3Q21



Questions during the call? QA@hedgeye.com

Thanks for watching! For more information, contact us at:

HealthCareTeam@hedgeye.com